Vimgreen Pharma Concludes Enrollment in phase 2 Trial of VG081821AC

Vimgreen Pharmaceuticals, a research-based pharmaceutical company specializing in adenosine signaling modulation, shared that they have finished enrolling participants in a phase 2 clinical trial for VG081821AC, a new drug for early-to-mid stage...

Domestic Pharmaceutical Retail market rises 11 percent in July

In July, the domestic pharmaceutical retail market witnessed a remarkable 11 percent increase. This phenomenon can be referred to as the flu impact. Increased sales of anti-infectives and pain relief suggest a rise in cases of flu and other viral...

Orchid Pharma Achieves Over Threefold Increase in Q1 2024 Net Profit

Orchid Pharma announced a consolidated net profit of Rs. In the first quarter ending on June 30, 2024, the revenue increased by over three times to Rs 32.95 crore, exceeding the Rs 9.4 crore recorded in the same quarter of the previous fiscal...

Biosyngen receives US FDA Nod to begin phase lI trial of Cell therapy

Biosyngen, a company focused on immuno-oncology, stated that its EBV-specific CAR-T cell therapy, BRG01, has received approval from the US Food and Drug Administration (FDA) to advance into a crucial phase II clinical trial. This is the initial...

India's 78th Independence Day Celebrating Pharma Leadership and Impact

On the occasion of India's 78th Independence Day, it is a time to look back on the incredible progress and successes achieved, especially in the pharmaceutical sector. Over the years, India has become a leading player in pharmaceutical innovation...

AstraZeneca & Daiichi Sankyo's Enhertu Receives Conditional Nod in China

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been conditionally approved in China for treating adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma after two or more prior...

Mabwell's Nectin-4 ADC Gains Breakthrough Status for Urothelial Carcinoma

Mabwell, a forward-thinking biopharmaceutical company with a complete industry chain, revealed that its new Nectin-4 targeting ADC has received Breakthrough Therapy Designation (BTD) from the Center for Drug Evaluation (CDE) of the National...

Sandoz Receives US FDA Nod for Enzeevu To improve Visual Acuity

The US FDA has approved Enzeevu (aflibercept-abzv) 2 mg vial kit and pre-filled syringe for intravitreal injection by Sandoz, the leading company in generic and biosimilar medicines worldwide. Enzeevu is recommended for enhancing and preserving...

Avalyn Announces Initiation of Phase 1b Clinical Trial for AP02

Avalyn Pharma Inc., a biopharmaceutical company in the clinical stage that specializes in developing inhaled treatments for severe pulmonary diseases, has started a Phase 1b clinical trial to assess the safety, tolerability, and pharmacokinetics...

Health Minister Unveils MDA Campaign 2024 to Remove Lymphatic Filariasis

Prataprao Ganpatrao Jadhav, the Union minister of state for health & family welfare, virtually initiated the second round of the Bi-annual Nationwide Mass Drug Administration (MDA) campaign aimed at eliminating lymphatic filariasis...

© 2025 India Pharma Outlook. All Rights Reserved.